Verily is collaborating with iRhythm to develop solutions aimed at improving the screening, diagnosis and management of patients with atrial fibrillation (AFib). AFib is the most common type of irregular heart rhythm, and can lead to blood clots, stroke, heart failure and other heart-related complications. Millions of patients in the U.S. today live with undiagnosed AFib. New, clinically integrated and user-friendly solutions could provide an early detection system to help identify and manage patients that may have otherwise gone undiagnosed until they had a significant cardiac event, such as a stroke.
This collaboration extends Verily’s work developing health management solutions for people with pre-existing conditions. Verily and iRhythm are combining capabilities, such as continuous monitoring, data analytics and cloud-based machine learning, to create innovative solutions for monitoring AFib. With a shared mission to improve peoples’ lives, Verily and iRhythm will also leverage user-centered design and next generation hardware to collect, organize and activate health information for improved patient care. Together, we’re exploring ways to enhance technology not only for monitoring and management, but for earlier intervention, and ultimately prevention.